Literature DB >> 33734333

Sorting biologic subtypes of primary CNS lymphoma.

Mark Roschewski1, James D Phelan1.   

Abstract

Entities:  

Year:  2021        PMID: 33734333      PMCID: PMC7976509          DOI: 10.1182/blood.2020009968

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

2.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.

Authors:  George W Wright; Da Wei Huang; James D Phelan; Zana A Coulibaly; Sandrine Roulland; Ryan M Young; James Q Wang; Roland Schmitz; Ryan D Morin; Jeffrey Tang; Aixiang Jiang; Aleksander Bagaev; Olga Plotnikova; Nikita Kotlov; Calvin A Johnson; Wyndham H Wilson; David W Scott; Louis M Staudt
Journal:  Cancer Cell       Date:  2020-04-13       Impact factor: 31.743

3.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

4.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

5.  How I treat T-cell chronic active Epstein-Barr virus disease.

Authors:  Catherine M Bollard; Jeffrey I Cohen
Journal:  Blood       Date:  2018-04-30       Impact factor: 22.113

6.  Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Authors:  Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt
Journal:  N Engl J Med       Date:  2018-04-12       Impact factor: 91.245

7.  Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.

Authors:  Matthew J Frigault; Jorg Dietrich; Maria Martinez-Lage; Mark Leick; Bryan D Choi; Zachariah DeFilipp; Yi-Bin Chen; Jeremy Abramson; Jennifer Crombie; Philippe Armand; Lakshmi Nayak; Chris Panzini; Lauren S Riley; Kathleen Gallagher; Marcela V Maus
Journal:  Blood       Date:  2019-07-18       Impact factor: 25.476

  7 in total
  2 in total

1.  The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.

Authors:  Xiaowei Zhang; Yuchen Wu; Xuefei Sun; Qu Cui; Xueyan Bai; Gehong Dong; Zifen Gao; Yaming Wang; Chunji Gao; Shengjun Sun; Nan Ji; Yuanbo Liu
Journal:  BMC Cancer       Date:  2022-02-20       Impact factor: 4.430

Review 2.  Altered Immune Response to the Epstein-Barr Virus as a Prerequisite for Multiple Sclerosis.

Authors:  Fabienne Läderach; Christian Münz
Journal:  Cells       Date:  2022-09-04       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.